{"id":"W3141372695","doi":"10.1016/s1470-2045(21)00034-6","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Clinical endpoint; Clinical trial; Estrogen receptor; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062193,0.0004756447,0.002331764,0.0001322141,0.0000993648,0.00002923351,0.0004830911,0.0001798179,0.0004314722],"category_scores_gemma":[0.00005702757,0.0003730007,0.00008176919,0.0008648651,0.0004567685,0.0003278388,0.0003616268,0.000810465,0.00003132568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001222526,"about_ca_system_score_gemma":0.001223746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008282925,"about_ca_topic_score_gemma":0.002697835,"domain_scores_codex":[0.996336,0.000641296,0.0009027992,0.0008396989,0.0004663384,0.0008138306],"domain_scores_gemma":[0.9974946,0.0003674177,0.0004751424,0.0008178459,0.0006364345,0.0002085006],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.3030126,0.04400807,0.02938606,0.000280704,0.004362649,0.002779641,0.06302731,0.001009377,0.4672002,0.00008402509,0.000948243,0.0839011],"study_design_scores_gemma":[0.3867896,0.01146732,0.5113239,0.001880643,0.001396089,0.0007895908,0.03543576,0.001503092,0.04345934,0.0001406372,0.004492774,0.001321241],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985802,0.003166675,0.0001660683,0.004376505,0.0003509767,0.004251107,0.0006441794,0.00005038966,0.00119213],"genre_scores_gemma":[0.991376,0.0007411645,0.003922397,0.001317318,0.0005170534,0.001685018,0.00009132913,0.00006405955,0.000285652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4819379,"threshold_uncertainty_score":0.9998722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05096464552649327,"score_gpt":0.3993410276253444,"score_spread":0.3483763820988511,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}